April 19, 2026 07:35 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Pushback from smartphone makers: Centre drops Aadhaar app pre-install plan — report | Meta eyes first wave of layoffs on May 20: Report | TCS breaks silence on Nida Khan: ‘No HR role, no power’ in Nashik case | ‘Panic reaction’: Rahul Gandhi on women’s bill, says PM Modi ‘wants to send a message’ | Adani Group shares rise as Gautam Adani becomes Asia’s richest, overtakes Mukesh Ambani | TCS Nashik ‘conversion’ case accused seeks anticipatory bail citing pregnancy | IT raids TMC candidate Debasish Kumar’s premises ahead of Bengal polls | Bengal SIR: Supreme Court allows voters restored by tribunal till April 21 and 27 to vote | 'Women won't spare you': PM Modi warns Opposition over resistance to quota bill | Vijay booked in 3 cases over poll code violation ahead of Tamil Nadu polls
UK COVID19
Pixabay

UK testing new drug to prevent COVID-19 development after Coronavirus contraction: Reports

| @indiablooms | Dec 26, 2020, at 02:33 pm

Moscow/Sputnik: UK scientists are testing a new drug to prevent people, who have been exposed to the coronavirus, from falling ill with COVID-19, media reported.
 

According to The Guardian, the antibody therapy has been developed by the University College London Hospitals and the AstraZeneca pharmaceutical company.

“If we can prove that this treatment works and prevent people who are exposed to the virus going on to develop Covid-19, it would be an exciting addition to the arsenal of weapons being developed to fight this dreadful virus,” virologist Catherine Houlihan, who is leading the study, said, as quoted by The Guardian.

The drug will provide patients with an immediate cocktail of antibodies that may protect them from COVID-19 for 6-12 months.

The medicine may be used as an emergency treatment both to hospital inpatients and care home residents.

The therapy may be also useful for those, who had contact with COVID-19 patients, and students, who live, study and socialize in big communities.

If approved, the drug will be available for public use in March or April.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.